Skip to main content Skip to search Skip to main navigation

PMDA: Information on the procedure for remote inspections

In January 2021, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) published the English translation of the document on remote inspections, Procedure for Remote Inspection as a Part of Compliance Inspection on Drugs and Regenerative Medical Products.

The document describes the specific procedure for a remote inspection in five points.  A further four points clarify how to proceed with the necessary documents. Three points deal with the video conferencing system in more detail.

The procedure is usually as follows:

  1. The PMDA announces the inspection to the applicant as a remote inspection; if necessary, there is a pre-inspection meeting.
  2. The PMDA confirms the schedule of the pre-inspection and the method of presenting documentation approximately one to two months prior to the main inspection.
  3. The applicant grants the inspector access to the cloud system or sends the documentation on CD or DVD to PMDA.
  4. Information on sampling condition/scope of documentation will be provided to the applicant 13 business days prior to the main inspection.
  5. Within 10 business days prior to the main inspection, the applicant shares the documentation with the inspector(s).
  6. A pre-inspection, during which the documents are checked, takes place within 10 business days; if there are any concerns to be examined, the applicant is informed.
  7. During the main inspection using a video conferencing system, documents that could not be reviewed during the pre-inspection will be reviewed and the applicant will be interviewed about the concerns identified during the pre-inspection.
  8. After the inspection, the applicant should take action on the unresolved concerns as soon as possible.

PMDA: Procedure for Remote Inspection as a part of compliance inspection on drugs and regenerative medical product 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: Draft Guidance on Responding to Form 483 Observations

FDA: Draft Guidance on Responding to Form 483 Observations

The US Food and Drug Administration (FDA) has issued a draft guidance on responding to Form FDA-483 observations following drug CGMP inspections. The document provides recommendations on how manufacturers should structure their responses and what information they should include.
Read more
Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Here's the answer:
Read more
Veterinary GMP 2026: The New Regulatory Framework

Veterinary GMP 2026: The New Regulatory Framework

Implementing Regulations (EU) 2025/2091 and 2025/2154 consolidate the GMP requirements for veterinary medicinal products into a distinct and legally binding framework for the first time. While establishing regulatory independence for the veterinary sector, they remain substantively aligned with the EU GMP Guide.
Read more
Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB, the European association of medical device Notified Bodies, sees the proposed MDR and IVDR revision as an opportunity to improve efficiency, transparency and predictability in conformity assessment.
Read more
EMA: GMP Documentation for the Sterilisation of an API

EMA: GMP Documentation for the Sterilisation of an API

The EMA Q&A on the quality of medicines has been updated with a new question: “What kind of GMP documentation is required for an API manufacturer performing sterilisation of an active substance?”

Read more
EMA: Updated Q&A on OOS Batches of ATMPs

EMA: Updated Q&A on OOS Batches of ATMPs

The EMA has revised its questions and answers on the use of out-of-specification (OOS) batches of authorised cell- and tissue-based ATMPs (“Questions and answers on the use of out-of-specification batches of authorised cell/tissue-based ATMPs”, Rev. 1, 2026).
Read more
Previous
Next